Evozyne: Funding, Investors & Team (Oct 2026)
Evozyne, headquartered in Chicago, Illinois, is a generative AI company that has a strong focus on therapeutic discovery and drug development. Specializing in protein design and molecular scale, the company's main objective is to revolutionize protein design in order to unleash the power of innovative proteins, effectively addressing intricate human and societal problems. Founded in 2020, Evozyne operates in the biotechnology sector.
Evozyne has raised $81.0M across 1 funding round on record, the most recent a Series B of $81.0M announced in Sep 2023.
That round is above the $6.0M median round size for Artificial Intelligence companies tracked on FundedIQ over the last two years.
Evozyne Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Evozyne Funding Rounds
Evozyne Founders and Leadership Team
No contact details are on record for this team yet.
Evozyne Funding Compared to Other Artificial Intelligence Startups
Evozyne's latest round of $81.0M is above the median round in Artificial Intelligence. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evozyne in Artificial Intelligence and Chicago
Companies Similar to Evozyne
Sirona Medical Inc. is addressing the needs of today’s radiology practices with a novel cloud-native platform…
Leading health plans, program providers, and over 100 communities across the U.S., rely on CredibleMind to…
RapidCanvas is an AI platform that combines the precision and automation of AI agents with the deep domain…
Labelbox is a collaborative data training platform that creates and manages labeled data for machine learning…
Clueso is an AI-driven support system for SaaS applications.
Dapta is a software-as-a-service company that provides a platform with minimal coding required to create APIs…
Factored was co-founded with renowned AI expert Andrew Ng (Stanford/AI Fund/Google Brain/Coursera) and…
Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor…
Lightsprint provides an AI-native product development platform that supports collaborative software…
Suki is a leading technology company that provides AI-powered voice solutions for healthcare. Its mission is…
Drylab is an AI-powered bioinformatics platform for biomedical data analysis, research workflows, and…
Gallatin is developing a logistics system that is tailored to the current requirements and limitations of the…
Evozyne Funding FAQs
What does Evozyne do?
Evozyne, headquartered in Chicago, Illinois, is a generative AI company that has a strong focus on therapeutic discovery and drug development. Specializing in protein design and molecular scale, the company's main objective is to revolutionize protein design in order to unleash the power of innovative proteins, effectively addressing intricate human and societal problems. Founded in 2020, Evozyne operates in the biotechnology sector.
How much funding has Evozyne raised?
Evozyne has raised $81.0M across 1 round on record. The most recent is a Series B of $81.0M announced in Sep 2023.
When did Evozyne last raise funding?
Evozyne's most recent funding round on record is a Series B of $81.0M, announced in Sep 2023.
Who founded Evozyne?
FundedIQ lists Andrew Ferguson (Founder) at Evozyne.
Where is Evozyne headquartered?
Evozyne is based in Chicago, Illinois, United States.
How many employees does Evozyne have?
Evozyne is in the 101-250 employee band.
How does Evozyne's funding compare to other Artificial Intelligence startups?
Evozyne's latest round of $81.0M is above the $6.0M median round size for Artificial Intelligence companies on FundedIQ across 7,243 tracked companies over the last two years.
About FundedIQ's Evozyne Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evozyne is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.